Tyrosine Kinase 2 (TYK2) is a non-receptor tyrosine kinase belonging to the Janus kinase (JAK) family, which also includes JAK1, JAK2, and JAK3. TYK2 plays a critical role in mediating signaling by type I interferons (IFN-α/β), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-23 (IL-23), and other cytokines. In the central nervous system (CNS), TYK2 is predominantly expressed in microglia, the resident immune cells of the brain, where it regulates neuroinflammatory responses that contribute to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS) [@oshea2015].
| Tyrosine Kinase 2 | |
|---|---|
| Protein Name | Tyrosine Kinase 2 |
| Gene Symbol | [TYK2](/genes/tyk2) |
| UniProt ID | [P29597](https://www.uniprot.org/uniprot/P29597) |
| PDB Structures | 4OLI, 5OUE, 7T2L, 5WE1 |
| Molecular Weight | 131 kDa |
| Length | 1,172 amino acids |
| Subcellular Localization | Cytoplasm; plasma membrane upon activation |
| Protein Family | Janus kinase (JAK) family |
| Expression | High in microglia, neurons, astrocytes |
TYK2 exhibits the characteristic domain architecture shared by all JAK family members. The protein comprises multiple functional domains arranged from N-terminus to C-terminus:
The FERM (Four-point-one, ezrin, radixin, moesin) domain is located at the N-terminus and is responsible for anchoring TYK2 to cytokine receptors. This domain mediates high-affinity association with the intracellular domains of type I IFN receptors (IFNAR1/IFNAR2), IL-10 family receptors, and IL-12/IL-23 receptor complexes. The FERM domain is essential for bringing TYK2 into proximity with activated receptors following cytokine binding.
The SH2-like domain (also called the SH2B orSrc Homology 2 domain) functions as a protein-protein interaction module. This domain participates in downstream signaling by recruiting STAT proteins and other signaling molecules. The SH2-like domain also contributes to maintaining TYK2 in an inactive conformation in the absence of ligand stimulation.
The pseudokinase domain (also called the JH2 domain or pseudokinase domain) represents a unique feature of the JAK family. Despite containing sequence similarity to kinase domains, the JH2 domain lacks catalytic activity due to critical mutations in conserved kinase motifs. However, this domain plays a crucial regulatory role by maintaining TYK2 in an inactive conformation in the absence of cytokine stimulation. The JH2 domain functions as an autoregulatory switch, preventing premature activation and inappropriate signaling. Mutations in this domain can lead to constitutive activation or loss of function, depending on their specific location.
The kinase domain (JH1) contains the actual enzymatic activity of TYK2. This domain catalyzes the phosphorylation of tyrosine residues on downstream substrates, including STAT proteins. The catalytic domain contains the characteristic kinase motifs required for ATP binding and phosphate transfer. TYK2 phosphorylates STAT1, STAT2, and STAT3 in response to type I IFN and other cytokine stimulation.
Within the CNS, TYK2 serves as a critical signaling intermediate for multiple pathways that regulate neuroinflammation and immune homeostasis:
TYK2 is the primary kinase mediating type I interferon (IFN-α/β) signaling in the brain. Following binding of IFN-α or IFN-β to the IFNAR receptor complex, TYK2 becomes activated and phosphorylates STAT1 and STAT2, leading to the formation of the ISGF3 complex (STAT1-STAT2-IRF9) that translocates to the nucleus to induce interferon-stimulated genes (ISGs). This pathway is particularly important in microglia, where it provides the first line of antiviral defense and regulates chronic neuroinflammatory states [1].
TYK2 participates in signaling by IL-10 family cytokines (IL-10, IL-22, IL-26) and IL-12 family cytokines (IL-12, IL-23, IL-27). These cytokines play complex roles in modulating neuroinflammation—IL-10 is generally anti-inflammatory, while IL-12 and IL-23 promote pro-inflammatory T helper 17 (Th17) responses. TYK2-mediated signaling in microglia and astrocytes influences the balance between protective and pathological neuroinflammation.
In microglia, TYK2 signaling regulates the production of cytokines, chemokines, and other inflammatory mediators. TYK2 activity modulates the expression of major histocompatibility complex (MHC) molecules, complement proteins, and phagocytic receptors. This regulation is critical for microglial surveillance, debris clearance, and immune presentation functions.
TYK2 influences T cell responses within the CNS by regulating cytokine production by antigen-presenting cells. The TYK2-dependent IL-12 and IL-23 pathways promote differentiation toward pro-inflammatory Th1 and Th17 subsets, while IL-10 signaling supports regulatory T cell (Treg) development. This balance is critical for maintaining immune homeostasis in the brain.
In Alzheimer's disease, TYK2-mediated neuroinflammation contributes to disease progression through multiple mechanisms:
Chronic Type I IFN Signaling: Elevated type I IFN signaling in AD microglia, mediated by TYK2, promotes a chronic inflammatory state characterized by increased production of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), reactive oxygen species (ROS), and nitric oxide (NO). This "microglial priming" state makes microglia more responsive to secondary stimuli and less effective at performing protective functions like amyloid clearance [2].
Impaired Amyloid Clearance: TYK2 signaling in microglia can interfere with amyloid-beta (Aβ) phagocytosis and degradation. Studies show that chronic IFN-β signaling downregulates expression of genes involved in lysosomal function and lipid metabolism, reducing the capacity of microglia to clear Aβ plaques. Genetic variants that increase TYK2 expression are associated with elevated AD risk.
Tau Pathology Propagation: TYK2 activity in astrocytes and microglia promotes secretion of exosomes containing phosphorylated tau, facilitating propagation of tau pathology across brain regions. The inflammatory milieu created by TYK2-mediated signaling also promotes neuronal tau phosphorylation through activation of stress-responsive kinases.
Synaptic Dysfunction: TYK2-dependent inflammatory signaling in neurons contributes to synaptic loss—the morphological correlate of cognitive decline in AD. Pro-inflammatory cytokines released from microglia can directly damage synapses and impair synaptic plasticity mechanisms.
In Parkinson's disease, TYK2 influences dopaminergic neuron survival through effects on neuroinflammation and cellular stress responses:
Altered Cytokine Signaling: TYK2-mediated signaling responds to α-synuclein aggregation by promoting inflammatory cytokine production in microglia. This creates a feedforward loop where inflammation drives more α-synuclein aggregation and propagation, while aggregated protein further activates microglia.
Dopaminergic Neuron Vulnerability: The substantia nigra pars compacta (SNpc) contains microglia with particularly high baseline activation states, making them more responsive to TYK2-mediated inflammatory signals. TYK2 activity in this region exacerbates neuroinflammation that selectively targets dopaminergic neurons.
Genetic Evidence: GWAS studies have identified TYK2 variants associated with PD risk. The TYK2 P1104A variant (rs34536443) shows a protective effect against PD, reducing microglial inflammatory responses and providing neuroprotection in cellular models [3].
Mitochondrial Dysfunction: TYK2 signaling can impact mitochondrial function in neurons through effects on inflammatory pathways. Chronic neuroinflammation mediated by TYK2 contributes to mitochondrial dysfunction, a key pathological feature of PD.
TYK2 was first identified as a genetic risk factor for MS through GWAS, and subsequent studies have confirmed its role in disease pathogenesis:
Genetic Association: The TYK2 variant rs34536443 (P1104A) provides strong protection against MS development. This hypomorphic variant reduces TYK2 kinase activity while maintaining sufficient signaling for essential immune functions, making it an attractive therapeutic target [4].
Demyelination: TYK2-dependent signaling in oligodendrocytes and microglia contributes to demyelination in MS. Inhibition of TYK2 in mouse models of experimental autoimmune encephalitis (EAE) reduces demyelination and improves clinical outcomes.
Therapeutic Targeting: TYK2 inhibitors show promise for MS treatment by reducing pathogenic immune responses while sparing protective antiviral immunity.
Emerging evidence links TYK2 to ALS pathogenesis:
Enhanced Inflammatory Responses: TYK2 activity is elevated in microglia and astrocytes in ALS models and patient tissue. This enhanced inflammatory response contributes to motor neuron damage.
Genetic Variants: TYK2 genetic variants have been associated with ALS risk in some populations, suggesting a role in disease susceptibility.
Therapeutic Potential: TYK2 inhibitors may provide neuroprotective effects in ALS by reducing inflammatory-mediated damage to motor neurons.
Deucravacitinib (BMS-986165): This is the first FDA-approved TYK2-selective inhibitor, currently indicated for psoriasis. Deucravacitinib binds to the pseudokinase domain (JH2), stabilizing the inactive conformation and preventing kinase domain activation. Its selectivity over JAK1/2/3 reduces the immunosuppressive side effects seen with broader JAK inhibitors. Clinical trials are underway evaluating deucravacitinib in neurodegenerative diseases [5].
Brepocitinib: This TYK2/JAK1 dual inhibitor has been evaluated in clinical trials for inflammatory diseases. Its dual mechanism provides broader immunosuppression but with increased side effect risk.
Tofacitinib: A pan-JAK inhibitor (JAK1/2/3, with some TYK2 activity) approved for rheumatoid arthritis and ulcerative colitis. Its use in neurodegenerative diseases is limited by broad immunosuppression.
Ruxolitinib: A JAK1/2 inhibitor with TYK2 activity, approved for myelofibrosis and polycythemia vera. Being evaluated for neuroinflammatory conditions.
Blood-Brain Barrier Penetration: Most current TYK2 inhibitors have limited CNS penetration, restricting their utility for neurodegenerative diseases. Developing brain-penetrant TYK2 inhibitors is an active area of research.
Selective vs. Broad Inhibition: Complete TYK2 loss-of-function causes immunodeficiency and increased infection risk. Partial inhibition (as achieved by the protective P1104A variant) may provide optimal therapeutic benefit with acceptable safety.
Biomarker Development: Identifying biomarkers that predict response to TYK2 inhibitors will be essential for patient selection in clinical trials.
Goldmann T, Zeller N, Raasch J, Kierdorf K, Staszewski O, Blank L, et al. TYK2 controls cell-non-autonomous prion pathology in glial cells. Nature Neuroscience. 2015. ↩︎
Wang J, Liu Y, Chen X, Zhang Q, Cheng W, Liu Y, et al. TYK2-mediated microglial type I interferon signaling promotes neuroinflammation in Alzheimer's disease. Acta Neuropathologica. 2023. ↩︎
Dang W, Zhang Y, Li S, Zhou W, Liu H. The role of TYK2 in Parkinson's disease: evidence from genetic and cellular studies. Brain. 2023. ↩︎
International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, et al. Genetic risk variants in the JAK-STAT pathway are associated with multiple sclerosis susceptibility. Nature Genetics. 2013. ↩︎
Chopsky J, Lee D, Patel M, Singh R. Deucravacitinib: a first-in-class TYK2 inhibitor for psoriasis. Nature Reviews Drug Discovery. 2022. ↩︎